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Abstract
Background Breast cancer is the most common invasive
cancer to affect women in the world. Studies showed
tumor-infiltrating lymphocytes can exhibit both beneficial
and harmful effects on the biology and clinical outcome of
breast cancer, the conclusion still remains incomplete.
Here, we conducted a meta-analysis to evaluate the rela-
tionship between tumor-infiltrating lymphocytes and breast
cancer.
Methods A comprehensive search strategy was used to
search relevant literatures in PubMed and the ISI Web of
Science. The correlation among TILs and breast cancer
clinicopathological features and prognosis was analyzed by
using Review Manager 5.3 and Stata 12.0.
Result Seventeen eligible studies consisting of 12,968
participants were included. We found that higher value of
tumor-infiltrating lymphocytes had no relationship with
breast cancer clinicopathological variables. Interestingly, it
was correlated with response to neoadjuvant chemotherapy
in majority (pooled RR 2.43, 95 % CI 1.99–2.97). More-
over, higher value of total tumor-infiltrating lymphocytes
(both intraepithelial and stromal) was associated with bet-
ter prognosis (pooled HR 0.88, 95 % CI 0.83–0.94),
whereas some subtypes predicted a worse prognosis.
Conclusion This meta-analysis indicated that high value
of total TILs is not associated with breast cancer clinico-
pathological features, but can predict a favorable outcome
for neoadjuvant chemotherapy in majority except for hor-
mone receptor (-) subtype. And higher total TILs (both
intraepithelial TILs and stromal TILs) may be the potential
better prognostic indicators, while some subtypes like PD-
1? TILs and Foxp3? TILs show a worse prognosis.
Keywords Tumor-infiltrating lymphocytes  Breast
cancer  Clinicopathological features  Prognosis
Introduction
Breast cancer is one of the most common invasive cancers to
affect women health in the world. In 2013, it has accounted
for 29 % of all new cancer cases and 14 % of all cancer
deaths, becoming the second highest cause of cancer death
in women after lung cancer [1, 2]. Nonetheless, due to the
understanding of the breast cancer biology and improvement
in early diagnosis and treatment, its mortality has steadily
declined. Currently, accumulating evidences have shown
that the malignancy and biological features of cancer depend
on its genetic abnormalities as well as the interplay between
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cancer cells and microenvironment. Conversely, conven-
tional researches concerned more about the biological fea-
tures and the prognosis based on the indicators of breast
cancer itself, such as histological grade, expression of the
hormone receptors (estrogen receptor and progesterone
receptor), proliferation marker-Ki67, and amplification sta-
tus of the HER2 gene et al. [3, 4]. However, recent studies
have reported that the tumor microenvironment, comprising
adipocytes, tumor-associated fibroblasts, immune cells,
extracellular matrix, cytokines and other factors, also plays an
important role in tumor formation, growth, invasion and
metastasis. Immune cells, like tumor-associatedmacrophages
(TAMs), studies indicated that TAMs generally play a pro-
tumoral role, and in the primary tumor, TAMs can stimulate
angiogenesis and enhance tumor cell invasion, motility, and
intravasation [5, 6]. Clinical evidences indicate the associa-
tion between high TAMs influx and poor prognosis in breast
cancer patients [7, 8]. Also, tumor-infiltrating lymphocytes
(TILs) have distinct roles in modulation of the tumor niche,
favoring or inhibiting carcinogenesis and cancer progression.
Moreover, some subtypes of lymphocytes secrete IL-6 and IL-
8, which in turn activate PI3K/AKT, NF-jB, STAT3 signal-
ing, and generate a positive feedback loop between the tumor
cells and immune microenvironment [9, 10].
Limited data showed that total TILs were associated
with a better prognosis [11, 12]. In breast cancer, TILs
existence before chemotherapy is a good phenomenon,
which prompts the therapeutic effect of neoadjuvant ther-
apy [13, 14]. But the type, density, and location of TILs in
breast cancer exhibit different values for assessing disease
prognosis and progression. The majority of TILs are
prominent CD8? T cells, which are the major effector cell
type, and have been linked to a better prognosis [15].
However, Foxp3? T cells or PD-1? T cells infiltration
mediates tumor immune escape and reminds a worse
prognosis [16]. Thus, subtypes of TILs can exert both
inhibitory and stimulatory effects on breast cancer and the
prognostic value of TILs remains complex and controver-
sial. To address this controversy, we conducted a meta-
analysis aimed to evaluate the total or subtype of TILs as a
potential prognostic marker for breast cancer and to




This systematic review and meta-analysis were conducted
according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement [17]. A
systematic literature search for the following tags: ‘‘tumor-
infiltrating lymphocytes and breast cancer’’ or ‘‘tumor-as-
sociated lymphocytes and breast cancer’’-related papers in
the electronic databases PubMed and the Web of Science
from January 1990 to July 2014 was conducted indepen-
dently by two investigators. The citation lists associated
with the studies, including review articles that were
retrieved in the search, were used to identify additional
relevant publications. The title and abstract of each study
identified in the search were scanned to exclude any clearly
irrelevant reports.
Selection criteria
The studies included in this meta-analysis were either
randomized controlled studies (RCTs) or observational
studies (case–control or cohort) that evaluated the associ-
ation between TILs and breast cancer. The criteria for
inclusion were as follows: (a) articles evaluating the rela-
tionship between TILs and parameters such as clinico-
pathological features and prognostic factors of breast
cancer; (b) articles containing sufficient published data to
determine an estimate of relative risk (RR) or hazard ratio
(HR) and a 95 % confidence interval (95 %CI); and
(c) full-text, original research articles published in English.
The following studies were excluded: (1) overlapping
articles or duplicate data; (2) non-English languages; (3)
the types of reviews, comments or letters; (4) articles
published in books; and (5) lacking information.
Data extraction
Data from eligible studies were independently extracted in a
standardized manner by the two investigators. Disagree-
ments in data extraction were resolved by consensus and by
referring back to the original article. The following data
were obtained from each article: first author’s last name;
year of publication; country of the population studied;
number of participants; duration of follow-up; the choice of
cutoff scores for the definition of positive staining or stain-
ing intensity; T category (T0–1, T2–4); N category; HER-2,
hormone receptor status; and most importantly, pathological
complete response (pCR) rate, the 5-year overall survival
(OS) and disease-free survival (DFS) rates.
The cutoff value for the TILs varied among studies, we
defined higher expression of TILs value according to the
original articles. And high TILs were defined as higher
value of total TILs on hematoxylin and eosin (H&E)-
stained sections. The T category was determined according
to the American Joint Committee on Cancer (AJCC) cancer
staging manual (one group T0–1, other group T2–4). We
defined hormone receptor positive either ER C1 % or PR
C1 % under immunohistochemistry (IHC), and classified
HER-2 positive if HER-2 gene amplification using in suit
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hybridization(ISH) or scored as 3? by IHC method. To
avoid bias from studies contributing very long-term follow-
up data compared with other studies, both OS and DFS
rates were standardized to include 5 years of follow-up in
all studies. For the articles that did not provide 5-year OS
and DFS rates directly, Kaplan–Meier curves were evalu-
ated using GetData Graph Digitizer 2.24 (http://
getdatagraph-digitizer.com).
Assessment of study quality
The qualities of 17 eligible studies included in our meta-
analysis were assessed according to the Newcastle–Ottawa
scale (NOS). The NOS contains eight items, which are
categorized into the three dimensions of selection, com-
parability, and outcome (cohort studies) or exposure (case–
control studies). The quality scores in NOS ranged from 0
(lowest) to 9 (highest) and studies with scores 6 or more
were rated as high quality. All included studies obtained
scores of 6 or more in the methodological assessment,
indicating that they were of high quality (Table 1).
Statistical analysis
This meta-analysis calculated the pooled RR or HR with its
corresponding 95 % CI to assess the association of TILs
with breast cancer using RevMan 5.3. Study heterogeneity
was measured using the Q test and I2 test. Fixed-effects
models (Mantel–Haenszel, P[ 0.1 and I2\ 50 %) assume
that the differences between the results of various studies
are due to chance. Random-effects models (DerSimonian
and Laird, P B 0.1 or I2 C 50 %) assume that the results
can genuinely differ between studies. In the absence of
heterogeneity, both fixed- and random-effects models
provide similar results. When heterogeneity is present, the
random-effects model is considered to be more appropriate
than a fixed-effects model, resulting in wider intervals and
a more conservative estimate of effect. The publication
bias on the reported outcomes was assessed with the con-
struction of contour-enhanced funnel plots and Egger’s
tests; this analysis was performed by STATA version 12.0.
Results
Search results and characteristics of eligible studies
Thedetailed search steps are described inFig. 1. Initially, 1833
potential articles were retrieved utilizing the search strategy
describedabove.After titles and abstractswere reviewed, 1679
articles were excluded. Thus, 154 full-text papers was viewed,
of these papers, another 135 were excluded because they did
not provide data between TILs and clinicopathological
features or specifywhether disease-free survival (DFS)/overall
survival (OS) rate was investigated. Finally, a total of 17
studies were included for the meta-analysis.
All features of the eligible studies in systematic review
and meta-analysis are summarized (Table 1). These
observational retrospective studies evaluated the level of
TILs and clinicopathological features or prognostic
parameters for breast cancer, consisting of approximately
12,968 participants with a median of 711 (from 68 to 3403)
per study and with a median follow-up of 73 months (range
39–180). Among them, five were from the Europe, four
from America, seven from Asia, and one from Africa,
which covered the most areas around the world.
Higher value of total TILs was not associated
with breast cancer clinicopathological features,
but some subtypes may have
High TILs value was not associated with certain clinical
parameters of breast cancer, such as grade category (G1–2
vs. G3): (pooled RR 0.93, 95 % CI 0.77–1.13); hormone
receptor status (? vs. -): (pooled RR 0.48, 95 % CI
0.07–3.32); or HER-2 status (? vs. -): (pooled RR 0.83,
95 % CI 0.61–1.12). So, we found that total TILs were not
associated with tumor grade, hormone receptor or HER-2
status. Unfortunately, we had not analyzed the relationship
of tumor size, lymph node status and Ki-67, due to the
limited quantity of literatures (Supplementary Figure 1).
It is already known that TILs in breast cancer have
several subtypes, such as CD8? T cell, PD-1? T cell and
Foxp3? T cell. Through the analysis, we found that PD-1?
TILs were related to high tumor grade (G1–2 vs. G3)
(pooled RR 0.63, 95 % CI 0.54–0.73), big tumor size (T1
vs. T2–4) (pooled RR 0.72, 95 % CI 0.62–0.82), positive
lymph node (? vs. -) (pooled RR 1.76, 95 % CI
1.50–2.07), negative hormone receptor (? vs. -) (pooled
RR 0.75, 95 % CI 0.66–0.84) and HER-2 status (? vs. -)
(pooled RR 1.53, 95 % CI 1.08–2.16). Both Foxp3? TILs
and CD8? TILs also had some relationships with breast
cancer clinicopathological parameters (Table 2).
Higher value of total TILs predicted a better
response to neoadjuvant chemotherapy in most
breast cancers, except hormone receptor negative
ones
We defined the pathological complete response (pCR), which
meant no residual invasive cancer cells in surgical specimens
of primary tumor and axillary lymph node. Six studies con-
taining 1970 patients were selected. The results showed over-
expression of total TILs predicted a higher pCR rate (pooled
RR 2.43, 95 % CI 1.99–2.97). Besides, high-TILs were also
associated with elevated pCR rate for hormone receptor (?),
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HER-2 (?), and HER-2 (-) breast cancer, respectively
(pooled RR were 2.24, 1.92, and 2.68, respectively) (Fig. 2).
Higher value of total TILs was significantly
associated with better prognosis, but several
subtypes revealed a worse result
Three studies (including a total of 2992 patients) that
demonstrated the association of total TILs and the long-
term survival were obtained from the published data. Meta-
analysis of the included papers reporting DFS and metas-
tasis-free survival in total TILs revealed a pooled HR of
0.88, with a 95 % CI of 0.83–0.98, which is statistically
significant (P\ 0.0001). Total TILs also indicate a long
overall survival, but without statistically significant
(P = 0.08). We also evaluated the prognostic utility of
TILs within intraepithelial (iTILs) and stromal compart-
ments (sTILs). The pooled data suggest both iTILs and
sTILs were associated with better DFS and cancer-specific
survival, estimated HRs in iTILs and sTILs being 0.90
(95 % CI 0.83–0.98) and 0.85 (95 % CI 0.76–0.94),
whereas they were not significantly correlated with OS (HR
in iTILs 0.90, 95 % CI 0.76–1.06 and HR in sTILs 0.91,
95 % CI 0.77–1.08) (Fig. 3).
In a subgroup analysis, both PD-1? TILs (polled HR
2.92, 95 % CI 1.81–4.72) and Foxp3? TILs (polled HR
3.86, 95 % CI 1.62–9.22) predicted poor overall survival.
But there exists no significance for disease-free survival
and cancer-specific survival. Breast cancer with high level
of CD8? TILs showed a favorable disease-free survival
(pooled HR 0.52, 95 % CI 0.30–0.69) (Fig. 4).
Wen-Chung Che’s research illustrated that interleukin-
17-producing TILs had a survival influence on breast
cancer, this study contained 207 breast cancer
patients, the result indicated that IL-17-producing TILs
were associated with high grade, hormone receptor (-)
subtype, and a poorer survival (disease-free survival 64.0
vs. 87.3 %; HR 2.68; 95 % CI 1.37–5.27; P\ 0.01) [18].
In addition, there was another small group called
cdT TILs in breast cancer. These cdT cells were very
common in breast cancer microenvironment, and pre-
dicted a better survival (recurrence-free survival: HR
41.69 95 %CI 5.4–321.96; P = 4.79 9 10-8. Overall
survival: HR 44.73 95 %CI 5.79–345.22, P =
1.51 9 10-8) [19].
Publication bias
Egger’s tests indicated that there was no evidence of sig-
nificant publication bias after assessing the funnel plot for
the studies included in our meta-analysis (Supplementary
Figure 2).
Discussion
The information about the prognostic and predictive value
of TILs in breast cancer is still limited. To our best
knowledge, the present meta-analysis is the first study to
systematically evaluate the association among TILs with
clinical–pathological features and prognostic factors in
breast cancer.
Fig. 1 Flowchart of the
selection of studies for inclusion
in the meta-analysis
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Correlation of TILs with clinicopathological
parameters
Total TILs in breast cancer are not strongly associated with
clinicopathological characteristics, the previous studies
showed that breast cancer with high differentiation, hor-
mone receptor (-) and HER-2 (?) would have a higher
level of TILs [13]. But our study did not achieve the
similar result; this might be related to very small available
raw data and lack of large size of sample research. But PD-
1? and Foxp3? subtype TILs highly expressed in hormone
receptor (-), HER-2(?) breast cancer, which have a high
risk of recurrence and metastasis. However, CD8? TILs as
the core of the local immune cells did not have relationship
with clinic pathological traits of breast cancer.
Relationship between TILs and neoadjuvant
chemotherapy response
Recently, the relationship between TILs and the response
of breast cancer with neoadjuvant chemotherapy have at-
tracted much attention. Most researches deem that rich of
TILs can improve the sensitivity and effect of neoadjuvant
chemotherapy. The reasons mainly include (Fig. 5): first,
influencing the factors about tumor immunosurveillance.
Chemotherapeutic drugs were selected for their direct
cytotoxic effects against highly proliferative tumor cells,
releasing tumor antigen, ATP and purinergic receptor.
Tumor cells expressed HLA-I had higher CD8? T cell
infiltration [20]. Besides, ATP-dependent pathway
whereby the intratumoral accumulation of granulocyte–
monocyte progenitors (GMPs) and inflammatory mono-
cytes facilitates the local differentiation of inflammatory
DCs and the activation of T cells against cancer [21].
Chemotherapy promoting chemokine expression in tumor
microenvironment affects leukocyte migration, such as
CCL2/CCR2 pathway reboots antigen-specific T cell
responses [22]. Otherwise, chemotherapy can induce IL-2
and IFNc secretion to trigger immunogenic cell death, and
increase the permeability of tumor cells to granzyme B,
thereby rendering them to be susceptible to CTL-mediated
lysis even if they do not express the antigen recognized by
CTLs [9]. Second, influencing the factors about tumor
immunosuppression. Regulatory T lymphocytes (Tregs)
and myeloid-derived suppressor cells (MDSCs) are major
components of these inhibitory cellular networks [23].
Compared with other immune cell, Tregs have a higher
proliferation rate and can be directly ‘‘killed’’ by
chemotherapy. Drugs, like cyclophosphamide, can impair
Treg-suppressive function by downregulating Foxp3 and
glucocorticoid-induced TNFR-related protein. The selec-
tive induction of Tregs apoptosis by paclitaxel was
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Fig. 2 The forest plot of RRs was assessed for association between
TILs and breast cancer short-term outcome (neoadjuvant chemother-
apy pCR rate). a TILs and breast cancer, b TILs and hormone
receptor (?) breast cancer, c TILs and hormone receptor (-) breast
cancer, d TILs and HER-2 (?) breast cancer, e TILs and HER-2 (-)
breast cancer
Fig. 3 The forest plot of HRs
was assessed for association
between total TILs and breast
cancer long-term prognosis.
a Total TILs and disease-free
survival/metastasis-free
survival, b total TILs and
overall survival
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Fig. 4 The forest plot of HRs was assessed for association between
subtypes of TILs and breast cancer long-time prognosis. a CD8? TILs
and disease-free survival/cancer-specific survival, b CD8? TILs and
overall survival, c PD-1? TILs and disease-free survival, d PD-1?
TILs and overall survival, e Foxp3? TILs and disease-free sur-
vival/cancer-specific survival, f Foxp3? TILs and overall survival
Fig. 5 A positive feedback
loop between TILs and breast
cancer chemotherapy
504 Clin Transl Oncol (2016) 18:497–506
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and downregulation of the antiapoptotic molecule Bcl-2 on
Tregs [24]. The antimetabolite like 5-fluorouracil at low
doses had also been shown to induce MDSCs apoptosis,
this selective effect was explained by a lower expression of
thymidylate synthase by MDSCs [25]. Docetaxel and
paclitaxel were shown to impair MDSCs suppressive
function, predominantly by blocking Stat3 phosphorylation
and by promoting MDSC differentiation into M1 macro-
phages or dendritic cells (DCs). Chemotherapy can also
inhibit immunosuppressive cytokines (including IL-4, IL-
10 and IL-13) while stimulating antitumor innate immunity
[20].
Our study reflected that high-TILs showed a better
treatment response of neoadjuvant chemotherapy, but
under subtype analysis, we found in hormone receptor (-)
breast cancer did not get the same result. This result dif-
fered from the Clinical Trial PrECOG0105 [26]. In 2014,
American Society of Clinical Oncology (ASCO), Shaveta
Vinayak reported that TILs were predictive of response to
platinum-based neoadjuvant therapy and were significantly
associated with triple-negative breast cancer (TNBC), the
causes and possible reasons for this difference may be the
chemotherapy agents, eligible studies in our analysis
almost used the anthracycline-based chemotherapy.
In 2013, San Antonio Breast Cancer Symposium
(SABCS), Sherene Loi reported that TILs were associated
with higher pCR rates after neoadjuvant trastuzumab and
chemotherapy in early-stage HER2-positive breast cancer
[27]. This research gave us a new message that tumor
targeted therapy and TILs had a complex relationship,
more studies were needed to explore TILs dynamic change
with trastuzumab treatment, and the mechanism [28].
Breast cancer is a kind of malignant tumor with high
heterogeneity, TILs as a marker for treatment need ade-
quate consideration about the molecular subtypes of cancer
and chemotherapy agents. Certain types of breast cancer
with appropriate level of chemotherapy enhance local
immune reaction and activate cytotoxic lymphocytes.
Immune reaction and conventional antineoplastic agents
play a double effect on breast cancer and finally improve
the therapeutic outcome.
Impact of TILs on long-term prognosis
Previous studies had shown that higher expression of total
TILs suggested a better prognosis of breast cancer, our
study also got the similar results. But we found that the
value for prognostic implication was not affected by TILs
location, both iTILs and sTILs contributed to a favorable
survival.
It is worth noting that different TILs subtypes have
different results. High level of PD-1? TILs or Foxp3? TILs
predicts a poor prognosis. PD-1? TILs or Foxp3? TILs can
suppress antitumor immune response and lead to escape
immune clearance, so the more the PD-1? TILs or Foxp3?
TILs were, the worse the prognosis of patients was [29,
30]. On the contrary, CD8? TILs indicated a good prog-
nosis [31]. These results therefore reflect that lymphocytes
in tumor microenvironment can affect the balance of
immune response and tolerance, leading to different
outcome.
Most studies indicated the association between TILs in
pre-treatment and long-term prognosis of breast cancer, but
what was it about TILs in residual lesions after neoadjuvant
therapy? M. V. Dieci proved that the higher concentration
of residual lesions TILs after neoadjuvant therapy pre-
dicted a better prognosis, and this is not affected by
chemotherapy cycle times [32]. So, TILs dynamics varia-
tion may be a good prognostic marker in breast cancer
microenvironment.
However, there still exist some limitations in the present
meta-analysis. First of all, the literatures in the meta-
analysis were based on observational studies, the correct-
ness of the result depended on the accuracy of the original
literature research, we therefore formulated the strict
inclusion and exclusion standard. Moreover, this study only
included the published literature in English and limited
quantity literatures, there might exist language bias and
study heterogeneity.
In conclusion, our study shows a significant correlation
between TILs and clinical traits in breast cancer patients.
Higher value of total TILs not only predicts neoadjuvant
chemotherapy response, but also implies a better prognosis,
whereas some subtypes of TILs, like PD-1? TILs and
Foxp3? TILs, are not amity with breast cancer and predict
an unfavorable outcome. But for hormone receptor (-)
breast cancer, neoadjuvant chemotherapy agent may affect
the TILs infiltrating, and lead to a different therapeutic
effect. So TILs should be monitored in breast cancer
patients for rational stratification and adjusting the treat-
ment strategy, further meticulous and deep researches
about TILs and breast cancer are also needed.
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